Mortality risk factors in lobectomies: Single-institution study

Original Papers • DOI: 10.2478/pneum-2019-0025 • 68 • 2019 • 130-137 Pneumologia Mortality risk factors in lobectomies: Single-institution study Bogdan I. Popovici1, Dana Matei2,3,*, Anca Daniela Farcas2,4,†, Milena Man2, Cornelia Popovici4, Romeo Chira2,4, Cornel Iancu2,3 1 Division of Thoracic Surgery, “Leon Daniello” Clinical Hospital of Pneumology Cluj Napoca, Romania “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca, Romania 3 “Prof. O. Fodor” Regional Institute of Gastroenterology and Hepatology, Surgery Department, Cluj-Napoca, Romania 4 Country Clinical Emergency Hospital Cluj-Napoca, Romania 2 Abstract English: The need to identify the risk factors (RFs) predictive of mortality after pulmonary lobectomy has fuelled several single- or multiinstitution studies, without establishing a prediction model of the generally accepted risk. Each single-institution study offers its own RFs, which corroborated with the RFs published in other multicentric studies may allow a better prediction of postoperative mortality for specific categories of patients. The aim of our study was to identify the 30-day mortality RFs in our lobectomy patients and to compare our results with those published in literature. We therefore analysed the influence of 49 perioperative parameters on postoperative mortality of consecutive lobectomy patients. The 192 lobectomy patients enrolled had malignant (81.25%) and infectious conditions (12.5%) and a 2.6% mortality rate. The results of our study support the following perioperative RF associated with a high mortality rate: thrombocytosis, chronic obstructive bronchopulmonary disease (COPD), digestive and hepatic comorbidities, neoadjuvant chemotherapy, tuberculosis, the American Society of Anesthesiologists rating and the characteristics of postoperative drainage. In conclusion, these RFs may serve as the factors to consider when calculating the mortality rate after lobectomy, in preoperative selection as well as in instruments for the assessment of postoperative results. Keywords pulmonary lobectomy • mortality • risk assessment Factori de risc asociați cu mortalitatea în lobectomii studiu unicentric Rezumat Romanian: Necesitatea identificării factorilor de risc (FR) predictivi ai mortalității postlobectomie a determinat apariția a numeroase studii uni sau multicentrice fără a se putea stabili un model de predicție al riscului general acceptat. Fiecare studiu unicentric susține FR proprii, care asociați cu cei precizați de studile multicentrice ar permite o predicție mai bună a mortalitătii postoperatorii pentru categorii speciale de pacienți. Scopul studiului nostru a fost de a identifica FR pentru mortalitatea la 30 de zile a pacienților cu lobectomie și compararea rezultatelor cu cele din literatura. Au fost analizați 49 parametri perioperatorii și influența asupra mortalității postoperatorii. Cei 192 pacienti înrolați au prezentat patologie malignă (81.25%) și infectioasă (12.5%) și au avut o mortalitate postoperatorie de 2.6%. Rezultatele studiului susțin ca FR perioperatori asociați cu o mortalitate crescută au fost trombocitoza, bronhopneumopatia cronica obstructiva, patologia hepato-digestiva, chimioterapia neoadjuvanta, tuberculoza, scor American Society of Anesthesiologists (ASA) crescut și caracteristicile drenajului postoperator. In concluzie, aceștia ar putea constitui factori necesari a fi luați în calculul riscului de mortalitate postlobectomie, în selecția preoperatorie precum și ca instrumente de evaluare a rezultatelor postoperatorii. Cuvinte-cheie lobectomie • motalitate • evaluarea riscului *Corresponding author: Dana Matei E-mail: [email protected] † Authors with equal contribution with first authors. Open Access. © 2019 Popovici et al., published by Sciendo This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License. 130 Popovici et al.: Mortality risk factors in lobectomies Abbreviations ASA – COPD – FEV1 – FEV25–75% – LLL LUL LVEF% ML NSCLC P/Y PaO2 PaCO2 – – – – – – – – PAPs ppoFEV1 – – RF RLL RUL SaO2 TB TLC% – – – – – – American Society of Anesthesiologists chronic obstructive bronchopulmonary disease forced expiratory volumes in 1 s forced expiratory flow during 25–75% of expirations left lower lobe left upper lobe left ventricle ejection fraction% medium lobe non-small-cell lung cancer (cigarette) packs per year partial pressure of oxygen in arterial blood partial pressure of carbon dioxide in arterial blood pulmonary artery pressures predicted postoperative forced expiratory volumes in 1 s risk factors right lower lobe right upper lobe Oxygen saturation (arterial blood) tuberculosis total lung capacity% Introduction Radical pulmonary resections are the most efficient option for the therapy of pulmonary cancer (1–3) and of other benign pulmonary conditions. Of all radical pulmonary resections, lobectomy is the most frequently used. Usually, this intervention has severe cardiac and respiratory consequences and it is performed on frail patients with several functional impairments and comorbidities (1). During the past four decades, several studies on the characteristics of patients at high mortality risk after pulmonary resection have been performed (4–7). These studies are “single-institution studies”, of limited size, and present the characteristics of the local patients and institution, making the results difficult to extrapolate to other institutions (2). Since these studies define sets of risk factors (RFs) specific to the group being analysed, they cannot be compared with the results of other institutions in order to assess the performance of the surgical act (8, 9). Including single-institution studies in large national or multinational databases may prove useful in creating a standard to which each institution may compare its surgical performance (6). This standard, despite its high statistical value, may not accurately reflect the experience of just a single institution (4). It follows that the best practice would be to perform studies assessing the local activity of each centre alongside including these data in large multiinstitutional databases. This study is based on the assumption that the mortality RFs of pulmonary lobectomies, identified through multiinstitutional studies (1, 5, 6), may be insufficient in correctly assessing mortality in our clinic. Specific factors, correlated with the particularities of the patients and of the institution, may be present. A risk prediction model, also including these factors, may be more useful in the accurate assessment of the surgical risk. The aim of this study was to assess the mortality predictive factors in consecutive patients having undergone lobectomy. In case of finding specific RFs, these factors may prove useful in improving the postoperative mortality prediction and in assessing the quality of the surgical act, both medically and legally. Material and method We enrolled in this study all consecutive patients having undergone lobectomy, especially for pulmonary cancer as well as for benign conditions. The surgical interventions were performed by the same anaesthesia/surgical team using a single protocol in a regional thoracic centre between 2008 and 2014. Following parameters were recorded: demographic data, preoperative functional status, comorbidities and particularities of each condition. We recorded in the database the neoplastic stages using the TNM 7 classification (7). Other parameters included the duration of surgery and the particularities of postoperative drainage, among others, amounting to 49 perioperative variables. The only postoperative variable recorded was the 30-day mortality rate, meant to determine which of the previous parameters may become mortality RFs after lobectomy. All patients signed an informed consent. The study was approved by the Ethics Committee of “Iuliu Hațieganu” University of Medicine and Pharmacy no 29/05.05.2018. The statistical analysis was performed using the IMB SPSS Statistics 2.0 software. We analysed over 49 pre- and intraoperative variables, 37 categorical and 12 continuous, in order to identify some possible correlations with postoperative mortality. The categorical variables were compared using the Chi-square teste (χ2) or Fisher test when necessary. For the continuous variables we identified the normally or abnormally distributed variables, expressed them as means or medians and tested them using the Student’s t and Mann–Whitney tests. 131 Pneumologia Using the univariate analysis, we identified which of the mentioned preoperative factors influenced postoperative mortality with statistical significance (p < 0.05). The variables identified were introduced in multivariate analysis in order to determine which may qualify as independent predictive factors. Results We enrolled 264 patients with major pulmonary resections, after excluding 34 because of incomplete medical data. Of these, 192 patients required lobectomy (72.7%), 20 bilobectomy (7.5%) and 52 pneumonectomy (19.7%). The mean age of patients was 57.4 ± 11.1 years (17–79 years); the majority were male (72.4%) and smokers of more than 20 packs of cigarettes per year (81.3%). The surgical indication was established for malignant (81.25% cases – of which 4.2% carcinoids), infectious [12.5% cases – of which 6.8% tuberculosis (TB)] and benign conditions (6.25% – including rare conditions). Two patients (1.04%) had TB in addition to their malignancy, and 8.5% of pulmonary tumours were either infected or associated with non-tuberculous infections. The 30-day postoperative mortality rate for lobectomy was 2.6%, for bilobectomy was 5% and for pneumonectomy was 5.9%. The patients’ functional characteristics and laboratory results are displayed in Table 1. The patients who expired were all male and had lower TLC, SaO2, PaO2, PaCO2 values, compared with those who survived, but the difference did not reach statistical significance. In addition, the former more often had leucocytosis, anaemia or thrombocytosis, but only the latter was statistically significant. Patients who died had a higher frequency of comorbidities apart from neuropsychiatric, osteoarticular, skin and metabolic conditions, diabetes mellitus and kidney failure (Table 2). Despite the higher incidence of cardiovascular, respiratory, urogenital and hepato-digestive diseases, only the latter and chronic obstructive disease (COPD) reached statistical significance. Furthermore, neoadjuvant chemotherapy was performed more frequently (with statistical significance) in patients who did not survive. The pathology data of patients with lobectomy are displayed in Table 3, which show a higher frequency of infections, especially TB, in patients who died (p < 0.05). Table 4 shows that these patients more frequently had an indication for emergency lobectomy, American Society of Anesthesiologists (ASA) classes III and IV and right-side lobectomy. The mean duration of surgery was 3.19 ± 1.02 h, without significant difference between the two groups of patients. The postoperative pleural drainage (detailed in Table 5) was more abundant in the first and second day after the surgery of patients who died. We considered as normal drainage the discharge of serosanguinous or citrine fluid, but not the postoperative haemorrhagic discharge, which we classified separately. The patients who did not survive had a larger quantity of drainage fluid, with a 650 mL cut-off for Day 1 (Se 60% and Sp 81.82%) and 550 mL for Day 2 (Se 40% and Sp 96.26%). Table 1. Functional and laboratory characteristics of patients Analysed factor All: 192 No. (%) Postoperative death No 187 (97.4%) Yes 5 (2.6%) p Age (years) 57.48 ± 11.11 57.35 ± 10.99 62.40 ± 15.58 0.317 Male sex 139 (72.4%) 134 (71.7%) 5 (100%) 0.325 Smoking [>20 packs per year (P/Y)] 156 (81.3%) 152 (81.3%) 4 (80.0%) 1.000 Total lung capacity% (TLC%) 77.73 ± 14.12 84.42 ± 14.85 77.55 ± 14.10 0.284 FEV1% 84.34 ± 16.68 80.04 ± 15.26 84.45 ± 16.75 0.561 FEV25–75% 74.43 ± 28.45 60.20 ± 29.22 74.82 ± 28.41 0.258 Oxygen saturation (arterial blood) (SaO2) 95.55 ± 2.89 96.64 ± 1.13 95.52 ± 2.92 0.393 Partial pressure of oxygen in arterial blood (PaO2) 81.35 ± 17.93 84.40 ± 8.40 81.27 ± 18.12 0.701 Partial pressure of carbon dioxide in arterial blood (PaCO2) 39.04 ± 5.22 40.52 ± 2.60 39.00 ± 5.27 0.522 pH 7.38 ± 0.05 7.37 ± 0.03 7.38 ± 0.05 0.581 Pulmonary artery pressures (PAPs) 28.74 ± 6.12 32.40 ± 2.51 28.65 ± 6.16 0.176 Left ventricle ejection fraction% (LVEF%) 0.846 55.09 ± 5.67 54.60 ± 4.45 55.10 ± 5.71 Leucocytosis 77 (40.1%) 73 (39.0%) 4 (80.0%) 0.159 Anaemia 103 (53.6%) 99 (52.9%) 4 (80.0%) 0.375 Thrombocytosis 20 (10.4%) 17 (9.1%) 3 (60.0%) 0.009 Inflammatory markers 117 (60.9%) 114 (61.0%) 3 (60.0%) 1.000 P value was considered significant if p < 0.05 132 Popovici et al.: Mortality risk factors in lobectomies Table 2. Comorbidities of lobectomy patients Analysed factor All: 192 No. (%) Postoperative death p No 187 (97.4%) Yes 5 (2.6%) Cardiovascular conditions 98 (51.0%) 95 (50.8%) 3 (60.0%) 1.000 Diastolic dysfunction 46 (24.0%) 44 (23.5%) 2 (40.0%) 0.595 Respiratory disease 79 (41.1%) 75 (40.1%) 4 (80.0%) 0.161 COPD 65 (33.9%) 61 (32.6%) 4 (80.0%) 0.046 Neuro-psychiatric conditions 16 (8.3%) 16 (8.6%) 0 (0.0%) 1.000 Metabolic diseases 41 (21.4%) 41 (21.9%) 0 (0.0%) 0.586 Diabetes mellitus 15 (7.8%) 15 (8.0%) 0 (0.0%) 1.000 Urogenital conditions 14 (7.3%) 13 (7.0%) 1 (20%) 0.318 Kidney failure 9 (4.7%) 9 (4.8%) 0 (0.0%) 1.000 Digestive conditions 36 (18.8%) 33 (17.6%) 3 (60.0%) 0.046 Osteoarticular conditions 15 (7.8%) 15 (8.0%) 0 (0.0%) 1.000 Skin diseases 6 (3.1%) 6 (3.2%) 0 (0.0%) 1.000 0.410 Associated cancers Number of comorbidities 19 (9.9%) 18 (9.6%) 1 (20.0%) 1.81 ± 1.717 1.80 ± 1.723 2.40 ± 1.517 0.440 55 (28.6%) 51 (27.3%) 4 (80%) 0.024 5 (2.6%) 5 (2.7%) 0 (0.0%) 1.000 Neoadjuvant chemotherapy Preoperative radiotherapy P value was considered significant if p < 0.05 Table 3. Pathological characteristics of patients having undergone lobectomy Analysed factor Associated infections TB Pathological diagnosis All: 192 No. (%) Postoperative death No 187 (97.4%) Yes 5 (2.6%) Nonspecific 40 (20.8%) 39 (20.9%) 1 (20.0%) TB 13 (6.8%) 11 (5.9%) 2 (40.0%) No infection 139 (72.4%) 137 (73.3%) 2 (40%) Without TB 179 (93.2%) 176 (94.1%) 3 (60%) With TB 13 (6.8%) 11 (5.9%) 2 (40.0%) Abscess 10 (5.2%) 10 (5.3%) 0 (0.0%) Benign 3 (1.6%) 3 (1.6%) 0 (0.0%) Bronchiectasis Adenocarcinoma 3 (1.6%) 3 (1.6%) 0 (0.0%) 68 (35.4%) 65 (34.8%) 3 (60.0%) Carcinoma 43 (22.4%) 43 (23.0%) 0 (0.0%) Other NSCLC 27 (14.1%) 27 (14.4%) 0 (0.0%) Sarcoma 9 (4.7%) 9 (4.8%) 0 (0.0%) Carcinoid 8 (4.2%) 8 (4.7%) 0 (0.0%) TB 11 (4.2%) 9 (4.8% 2 (18.8%) 0 (0.0%) Other rare findings p 0.001 0.036 0.155 9 (4.7%) 9 (4.8%) Malignant conditions 157 (81.8%) 154 (82.4%) 3 (60%) 0.225 Benign conditions 35 (18.2%) 33 (17.6%) 2 (40.0%) 0.225 IA 11 (5.7%) 9 (4.8%) 2 (40.0%) 0.054 IB 31 (16.1%) 31 (16.6%) 0 (0.0%) IIA 36 (18.8%) 36 (19.3%) 0 (0.0%) IIB 35 (18.2%) 34 (18.2%) 1 (20.0%) IIIA 26 (13.5%) 26 (13.9%) 0 (0.0%) IIIB 7 (3.6%) 7 (3.7%) 0 (0.0%) IV 4 (2.1%) 4 (2.1%) 0 (0.0%) TNM 7 stages P value was considered significant if p < 0.05 133 Pneumologia It follows that 950 mL of pleural fluid drained during the first 2 days correlates with a higher mortality risk, at 60% Se and 81.82% Sp. The mortality rate was significantly higher in case of haemorrhagic drainage exceeding 1,500 mL in the first 48 h. The multivariate analysis showed that none of the analysed RFs, namely preoperative thrombocytosis, COPD or hepato-digestive conditions, neoadjuvant chemotherapy, associated TB, >550 mL drained fluid on the second day and postoperative haemorrhage exceeding 1,500 mL in the first 48 h, had a predictive ability for postoperative mortality (Table 6). It is noteworthy that, despite not reaching statistical significance, TB and thrombocytosis Table 4. Characteristics of the anaesthesia and surgery Analysed factor All: 192 No. (%) Postoperative death p No 187 (97.4%) Yes 5 (2.6%) Previous thoracotomy 7 (3.6%) 7 (3.7%) 0 (0.0%) Emergency lobectomy 6 (3.1%) 5 (2.7%) 1 (20%) 0.148 8 (4.2%) 8 (4.3%) 0 (0.0%) <0.001 1 (20.0%) ASA Lobectomy I II 79 (41.1%) 78 (41.7%) III 104 (54.2%) 101 (54.0%) 3 (60.0%) IV 1 (0.5%) 0 (0.0%) 1 (20.0%) Right upper lobe (RUL) 49 (25.5%) 47 (25.1%) 2 (40.0%) Medium lobe (ML) 12 (6.3%) 12 (6.4%) 0 (0.0%) Right lower lobe (RLL) 44 (22.9%) 41 (21.9%) 3 (60.0%) Left upper lobe (LUL) 47 (24.5%) 47 (25.1%) 0 (0.0%) Left lower lobe (LLL) 40 (20.8%) 40 (21.4%) 0 (0.0%) 3.19 ± 1.02 3.20 ± 1.03 3.02 ± 1.04 Duration of intervention 1.000 0.188 0.704 P value was considered significant if p < 0.05 Table 5. Characteristics of postoperative pleural drainage in the study group Analysed factor Drainage Day 1 (mL) Drainage Day 1 >650 mL (cut-off) Drainage Day 2 (mL) All: 192 No. (%) Postoperative death p No 187 (97.4%) Yes 5 (2.6%) 497.92 ± 226.91 492.51 ± 221.00 700 ± 367.42 37 (19.3%) 34 (18.2%) 3 (60.0%) 0.050 273.70 ± 139.70 268.72 ± 128.67 460.00 ± 343.51 0.002 0.007 Drainage Day 2 >550 mL (cut-off) 0.043 9 (4.7%) 7 (3.7%) 2 (40%) Drainage Day 1 + Day 2 >950 mL (cut-off) 37 (19.3%) 34 (18.2%) 3 (60.0%) 0.050 Haemorrhage Day 1 >1,000 mL 12 (6.3%) 11 (5.9%) 1 (20.0%) 0.278 Haemorrhage Day 1 + Day 2 >1,500 mL 13 (6.8%) 11 (5.9%) 2 (40.0%) 0.038 P value was considered significant if p < 0.05 Table 6. The impact of RFs on mortality in lobectomies as found in multivariate analysis Variable/RF Exp (B) Sig. Thrombocytosis 7.41 COPD Digestive conditions 95% CI for Exp (B) Lower Upper 0.142 0.51 107.77 2.45 0.543 0.14 44.16 4.89 0.2566 0.32 75.69 Neoadjuvant chemotherapy 2.03 0.615 0.13 31.69 TB 11.39 0.098 0.64 203.35 Drainage Day 2 >550 mL 2.63 0.580 0.15 221.42 Haemorrhage >1,500 mL 5.84 0.314 0.15 221.42 P value was considered significant if p < 0.05 134 Popovici et al.: Mortality risk factors in lobectomies were correlated with an increase in mortality risk of 11.39and 7.41-folds, respectively. Discussion Two hundred and ninety-four patients who consecutively underwent lobectomy or radical pneumectomy were evaluated. Conditions associated with high mortality rate in our study were: thrombocytosis, COPD, digestive and hepatic comorbidities, neoadjuvant chemotherapy, TB, high ASA score and the characteristics of postoperative drainage. Several studies, either single- or multi-institutional, have analysed several RFs in the search of those capable to predict the 30-day mortality. Despite the fact, that there is no accepted model for the prediction of mortality after lobectomy (10), the studies have identified several mortality RFs that deserve consideration. For instance, Brunelli and colab (5), while analysing the data of the European Society of Thoracic Surgeons Data Base, including around 48,000 anatomic resections of which 36,376 lobectomies, found the following parameters to predict mortality independently: male sex, age, predicted postoperative forced expiratory volumes in 1 s (ppoFEV1), coronary ischaemic disease, cerebrovascular disease, body mass index and thoracotomy. In an American study, performed by the Society of Thoracic Surgeons (1), the analysis of over 27,000 resections yielded a series de new predictive factors, completing the European model for the prediction of mortality risk: steroids, peripheral vascular disease, renal dysfunction, the Zubrod score, the ASA rating, induction therapy, tumour stage and extension of resection, re-interventions and the thoracotomy approach. The study performed on the national French database Epithor (6), including over 18,000 resections, has identified the following mortality RFs: age, sex, the ASA score, performance status, forced expiratory volume, body mass index, the side and type of lung resection, the need for extended resection, stage and number of comorbidities per patient. Another study (8) performed on around 3,000 lobectomies found other independent RFs: hypoalbuminaemia, “do not resuscitate” status, transfusions of more than four blood units, age, disseminated cancer, impaired sensorium, prothrombin time, type of operation and dyspnoea, while the study performed by Jean et al. (10) mentions dyspnoea at rest, dyspnoea on exertion and dysnatraemia. It follows that the aforementioned literature does not offer the basis for a generally applicable prediction model for 30-day mortality after lobectomy (9, 11) which makes the analysis of each local group essential in finding risk models specific to each institution. In these circumstances, our study analysed 49 presumed perioperative RFs for 30-day mortality, on a group of 192 consecutive patients having undergone lobectomy; we identified a series of clinical, biological, pathological and surgical/anaesthetic characteristics found more frequently in patients who did not survive than in those who did. In our study, the 30-day mortality rate in lobectomy patients was 2.6%, similar to that previously published. All deceased patients were male, since the male sex is a RF confirmed by other studies (1, 5, 6). In addition, we found several other RFs found more frequently in deceased patients, with differences sometimes reaching statistical significance: thrombocytosis, COPD, hepatic or digestive conditions, induction chemotherapy, ASA classes III and IV and the presence of suppurations, especially TB. Thrombocytosis (a platelet count above 40 x 104/mL) was defined as a RF for increased morbidity and mortality in oncological surgery for colorectal (12), gynaecological (in association with leucocytosis) (13) and pulmonary cancers (14). Kim et al. (14) found that preoperative thrombocytosis increases the mortality 2.47-fold in non-small-cell lung cancer (NSCLC) patients. In our study, thrombocytosis was more frequent than in Kim et al.’s study (10.4 vs 7.5%) and correlated with a 7.41-fold higher mortality risk in patients with varied pulmonary conditions. A possible explanation of the differences in study results may reside in our large number of cases associating nonspecific or TB infection to the neoplasia. Furthermore, our group also included patients in whom the surgical indication was prompted by the infectious condition. To our knowledge, none of the above-mentioned studies found infections as a 30-day mortality risk and yet, the high incidence of infections (specific and nonspecific) we found in patients who did not survive warns that they should be considered an individual RF for a certain category of patients. In addition, in our study, pulmonary TB increased the mortality risk 11.39-fold but did not validate as an independent RF due to the lack of statistical significance. COPD (GOLD 1–3), frequent in patients undergoing surgery, is also an independent RF for death in these patients (1, 15–17). In our study, despite its significantly higher prevalence in patients who died, the multivariate analysis did not confirm it as an independent mortality RF. Digestive conditions, especially toxic liver disease, further weaken these patients by altering the albumin levels and coagulation tests, increasing the risk of death 4.89-fold, but without having an independent predictive value. The published data are consistent in stating neoadjuvant chemotherapy as having a severe impact on morbidity and mortality after lung resections, leading to a 2.4% mortality rate (18–21), confirmed by our study. A high incidence of ASA classes III and IV in deceased patients confirms the data in literature but a higher mortality rate in 135 Pneumologia patients with right-side lobectomies, as found in our study, has not been previously mentioned. Further studies focused on this issue may provide pathophysiological explanations for this finding, as well as therapeutic implications in order to decrease mortality. In our study, of the postoperative parameters, we chose only pleural drainage, considering it as a direct consequence of the surgical act (22). Drainage of serous/citrine pleural fluid was the desired postoperative outcome, since the process allows its early removal with all the subsequent advantages (early mobilization, decreased infectious risk, increased compliance to respiratory physiotherapy) (23). In our clinic, the drainage after lobectomy involves two drains which are removed when the fluid becomes serous/ citrine and falls below 200–300 mL. The analysis of our data found that volumes of at least 650 mL on the first day and 550 mL on the second day may identify patients at higher mortality risk. These volumes may be caused by inflammatory conditions in the lung or pleura, difficult or late postoperative haemostasis or difficult expansion of the remaining parenchyma. In addition, some factors such as hypoalbuminaemia or haemodynamic imbalances may lead to prolonged drainage and higher mortality. Furthermore, haemorrhagic drainage, exceeding 1,500 mL in the first 48 h, was also associated with higher mortality. This association, despite good intraoperative haemostasis, may suggest general (hepatopathies, vascular conditions, etc.) or local factors (pleural adhesions, pleural and pulmonary suppurations, TB, lung diseases which make the expansion of the remaining parenchyma difficult). In our experience, the cases in whom haemodynamic stabilization was obtained by specific intensive care procedures and who did not develop large intrapleural clots did not require further interventions for haemostasis. Despite the differences found between patients who died and those who survived, the multivariate analysis did not yield any independent 30-day mortality predictors, probably due to the low number of deaths. One explanation of this fact may reside in certain limitations of our study: (a) the relatively short interval of analysis – the 90-day mortality analysis may provide further information; (b) the size of our study group as well as the low number of deaths; (c) the selection of variables, based on the analysis of medical records (for instance, the lack of important parameters such as diffusion lung capacity for carbon monoxide (DLCO), ppoFEV1, albumin levels, etc.); (d) the use of thoracotomy alone, known to be a mortality predictor (1, 5, 10), rather than the minimally invasive approach preferable to thoracotomy (24–26), which may all distort the results. Despite these limitations, the results of our study may serve as the foundation for a basic model for the prediction 136 of postoperative risk specific to the study group or to other similar groups, to be improved by further studies in the field. Conclusion When multicentric studies do not provide a generally applicable predictive model for 30-day mortality after lobectomy, our single-institution study suggests that factors such as thrombocytosis, COPD, liver and digestive conditions, induction chemotherapy, the ASA rating, associated suppurations – especially TB, the volume and characteristics of pleural drainage may constitute the necessary factors to be considered in calculating the mortality rate after lobectomy, in preoperative selection as well as in assessing the postoperative results. Ethics approval and consent to participate The study was approved by the Ethics Committee of “Iuliu Hațieganu” University of Medicine and Pharmacy no 29/05.05.2018. Conflicts of interest The authors declare that they have no conflicts of interest. References 1. Fernandez FG, Kosinski AS, Burfeind W, Park B, DeCamp MM, Seder C, et al. The society of thoracic surgeons lung cancer resection risk model: Higher quality data and superior outcomes. The Annals of Thoracic Surgery. 2016;102(2): 370–377. 2. Bernard A, Ferrand L, Hagry O, Benoit L, Cheynel N, Favre JP. Identification of prognostic factors determining risk groups for lung resection. The Annals of Thoracic Surgery. 2000;70(4): 1161–1167. 3. Ferguson MK, Reeder LB, Mick R. Optimizing selection of patients for major lung resection. The Journal of Thoracic and Cardiovascular Surgery. 1995;109(2): 275–283. 4. Kamel MK, Lee B, Harrison S, Port JL, Pua B, Altorki NK, et al. Do the surgical results in the National Lung Screening Trial reflect modern thoracic surgical practice? The Journal of Thoracic and Cardiovascular Surgery. 2019;157(5): 2038. e1–2046.e1. 5. Brunelli A, Salati M, Rocco G, Varela G, Van Raemdonck D, Decaluwe H, et al. European risk models for morbidity (EuroLung1) and mortality (EuroLung2) to predict outcome following anatomic Popovici et al.: Mortality risk factors in lobectomies 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. lung resections: An analysis from the European Society of Thoracic Surgeons database. European Journal of Cardio-Thoracic Surgery. 2016;51(3): ezw319. Bernard A, Rivera C, Pages PB, Falcoz PE, Vicaut E, Dahan M. Risk model of in-hospital mortality after pulmonary resection for cancer: A national database of the French Society of Thoracic and Cardiovascular Surgery (Epithor). The Journal of Thoracic and Cardiovascular Surgery. 2011;141(2): 449–458. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World Journal of Radiology. 2012 Apr 28;4(4): 128–134. Harpole DH, DeCamp MM, Daley J, Hur K, Oprian CA, Henderson WG, et al. Prognostic models of thirty-day mortality and morbidity after major pulmonary resection. The Journal of Thoracic and Cardiovascular Surgery. 1999;117(5): 969–979. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Available from: https:// academic.oup.com/annonc/article-abstract/28/suppl_4/ iv1/3958156. Jean RA, DeLuzio MR, Kraev AI, Wang G, Boffa DJ, Detterbeck FC, et al. Analyzing risk factors for morbidity and mortality after lung resection for lung cancer using the NSQIP database. Journal of the American College of Surgeons. 2016;222(6): 992.e1–1000.e1. Salati M, Brunelli A. Risk stratification in lung resection. Current Surgery Reports. 2016;4(11): 37. Mohamud M, Osborne L, Jones HG, Ahmed A, Beynon J, Harris DA, et al. Thrombocytosis as a marker for postoperative complications in colorectal surgery. Gastroenterology Research and Practice. 2018;2018: 1–5. Andersen CL, Eskelund CW, Siersma VD, Felding P, Lind B, Palmblad J, et al. Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer? Gynecologic Oncology. 2015;139(2): 312–318. Kim M, Chang H, Yang H, Kim YJ, Lee C-T, Lee J-H, et al. Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World Journal of Surgical Oncology. 2014; 12(1): 37. Gupta H, Ramanan B, Gupta PK, Fang X, Polich A, Modrykamien A, et al. Impact of COPD on postoperative outcomes. Chest. 2013;143(6): 1599–1606. 16. Saji H, Miyazawa T, Sakai H, Kimura Y, Tsuda M, Wakiyama Y, et al. Survival significance of coexisting chronic obstructive pulmonary disease in patients with early lung cancer after curative surgery. Thoracic Cancer. 2018;9(1): 19–24. 17. Yasuura Y, Maniwa T, Mori K, Miyata N, Mizuno K, Shimizu R, et al. Quantitative computed tomography for predicting cardiopulmonary complications after lobectomy for lung cancer in patients with chronic obstructive pulmonary disease. General Thoracic and Cardiovascular Surgery. 2019;67(8): 697–703. 18. Peer M, Stav D, Cyjon A, Sandbank J, Vasserman M, Haitov Z, et al. Morbidity and mortality after major pulmonary resections in patients with locally advanced stage IIIA non-small cell lung carcinoma who underwent induction therapy. Hear, Lung & Circulation. 2015;24(1): 69–76. 19. Venuta F, Anile M, Diso D, Ibrahim M, De Giacomo T, Rolla M, et al. Operative complications and early mortality after induction therapy for lung cancer. European Journal of Cardio-Thoracic Surgery. 2007;31(4): 714–717. 20. Stamatis G, Eberhard W, Pöttgen C. Surgery after multimodality treatment for non-small-cell lung cancer. Lung Cancer. 2004;45: S107–S112. 21. Refai M, Brunelli A, Rocco G, Ferguson MK, Fortiparri SN, Salati M, et al. Does induction treatment increase the risk of morbidity and mortality after pneumonectomy? A multicentre case-matched analysis. European Journal of Cardio-Thoracic Surgery. 2010;37(3): 535–539. 22. Satoh Y. Management of chest drainage tubes after lung surgery. General Thoracic and Cardiovascular Surgery. 2016;64(6): 305–308. 23. Coughlin S, Emmerton-Coughlin H, Malthaner R. Management of chest tubes after pulmonary resection: A systematic review and meta-analysis. Canadian Journal of Surgery. 2012;55(4): 264–270. 24. Rizzardi G, Bortolotti L. Risk factors and 90-day mortality after video-assisted thoracoscopic lobectomy for lung cancer: The discussion is still open. Video-Assisted Thoracoscopic Surgery. 2018;3: 2. 25. Brunelli A, Dinesh P, Woodcock-Shaw J, Littlechild D, Pompili C. Ninety-day mortality after video-assisted thoracoscopic lobectomy: Incidence and risk factors. The Annals of Thoracic Surgery. 2017;104(3): 1020–1026. 26. D’Amico TA. Defining and improving postoperative care. The Journal of Thoracic and Cardiovascular Surgery. 2014;148(5): 1792–1793. 137